BILAWITH-M Tablets

Bilastine 20 mg + Montelukast Sodium equivalent to Montelukast 10 mg

BILAWITH-M is a prescription anti-allergic combination containing Bilastine 20 mg and Montelukast 10 mg. Bilastine is a selective peripheral H1-antihistamine, while montelukast blocks leukotriene receptors. Together, these medicines act on two different pathways involved in allergic symptoms.

---

1. Product Information

---

2. What is BILAWITH-M Used For?

BILAWITH-M combines an antihistamine with a leukotriene receptor antagonist and may be prescribed for selected allergic conditions.

Potential clinical applications include:

• Allergic rhinitis
• Seasonal allergic rhinitis
• Perennial allergic rhinitis
• Allergic rhinoconjunctivitis
• Sneezing
• Runny nose
• Nasal itching
• Allergy-associated ocular symptoms
• Selected patients with allergic airway disease where montelukast is considered appropriate

Bilastine 20 mg is indicated in adults and adolescents aged 12 years and above for symptomatic treatment of allergic rhinoconjunctivitis and urticaria in the product information reviewed.

Montelukast is used for allergic rhinitis and asthma in appropriate patients, but its use for allergic rhinitis has important safety considerations because of its neuropsychiatric warning.

The fixed-dose combination BILAWITH-M should be promoted only for indications supported by its current Indian approval/licence.

---

3. How BILAWITH-M Works

Bilastine 20 mg

Bilastine is a second-generation, long-acting H1-antihistamine.

During an allergic reaction, histamine contributes to symptoms such as:

• Sneezing
• Nasal itching
• Runny nose
• Watery eyes
• Itching
• Redness

Bilastine selectively blocks peripheral H1 histamine receptors, reducing histamine-mediated allergic symptoms.

Bilastine is described as a non-sedating, long-acting peripheral H1 receptor antagonist, with clinical evidence for relief of allergic rhinoconjunctivitis and urticaria symptoms.

---

Montelukast 10 mg

Montelukast is a leukotriene receptor antagonist.

Leukotrienes are inflammatory mediators involved in allergic and airway responses. Montelukast blocks the CysLT1 receptor, thereby reducing leukotriene-mediated effects.

Montelukast can help control symptoms of allergic rhinitis and is also used as part of long-term asthma management in appropriate patients. It is not a rescue medicine for an acute asthma attack.

---

4. Combined Mechanism of Action

BILAWITH-M acts through two complementary pathways:

Histamine pathway

Bilastine → H1 receptor blockade → reduced histamine-mediated allergy symptoms

Leukotriene pathway

Montelukast → CysLT1 receptor blockade → reduced leukotriene-mediated inflammatory effects

This dual pharmacological approach may be considered for selected patients when the treating physician determines that both pathways need to be addressed.

---

5. Therapeutic Benefits

When prescribed appropriately, BILAWITH-M may help with:

• Reduction of sneezing
• Relief of nasal itching
• Reduction of runny nose
• Reduction of allergy-related symptoms
• Relief of allergic rhinoconjunctivitis symptoms
• Reduction of histamine-mediated manifestations
• Reduction of leukotriene-mediated inflammatory activity

Bilastine 20 mg has demonstrated improvement in symptoms including sneezing, nasal discharge, nasal itching, nasal congestion, ocular itching and tearing in allergic rhinoconjunctivitis.

---

6. Common Clinical Applications

Allergic Rhinitis

Allergic rhinitis may present with:

• Sneezing
• Runny nose
• Nasal congestion
• Nasal itching
• Watery eyes
• Ocular itching

Bilastine addresses the histamine component, while montelukast acts on the leukotriene pathway.

Seasonal Allergic Rhinitis

Seasonal allergens such as pollen can trigger recurrent nasal and ocular symptoms. Bilastine 20 mg is established for symptomatic treatment of seasonal allergic rhinoconjunctivitis.

Perennial Allergic Rhinitis

Patients exposed to allergens throughout the year may experience persistent or recurrent symptoms. Treatment should be individualized according to the clinical presentation.

Urticaria

Bilastine 20 mg is also used for symptomatic treatment of urticaria, including itching and wheal formation.

However, because BILAWITH-M contains montelukast, the specific indication for the fixed-dose combination should follow its approved product information rather than being inferred from the individual ingredients.

---

7. Suggested Use & Dosage

BILAWITH-M should be taken according to the physician’s prescription.

Each tablet contains:

• Bilastine — 20 mg
• Montelukast Sodium — equivalent to Montelukast 10 mg

For bilastine alone, product information commonly specifies 20 mg once daily in adults and adolescents aged 12 years and above for allergic rhinoconjunctivitis and urticaria.

However, the dosing schedule for the BILAWITH-M fixed-dose combination should be based on its approved prescribing information.

Important administration point for Bilastine

Bilastine 20 mg should generally be taken 1 hour before or 2 hours after food or fruit juice, because food and fruit juice can reduce its absorption.

For website content, this instruction should be retained only if it is consistent with the final approved prescribing information supplied with the product.

---

8. How to Take BILAWITH-M

• Take exactly as prescribed.
• Swallow the tablet with water.
• Do not crush or chew unless specifically instructed.
• Avoid taking bilastine with food or fruit juice.
• Follow the prescribed timing in relation to meals.
• Do not increase the dose without medical advice.
• Do not take an extra tablet for a missed dose unless instructed by your doctor.

Fruit juices can reduce bilastine exposure; water is the preferred beverage for administration.

---

9. Possible Side Effects

Bilastine-related

Possible adverse effects include:

• Headache
• Dizziness
• Fatigue
• Abdominal discomfort
• Nausea
• Diarrhoea

Bilastine clinical information identifies headache as a common adverse reaction and dizziness, fatigue and certain gastrointestinal effects among less frequent reactions.

Montelukast-related

Possible adverse effects include:

• Headache
• Abdominal pain
• Nausea
• Diarrhoea
• Upper respiratory symptoms

Montelukast also carries an important warning regarding serious neuropsychiatric events.

---

10. Important Montelukast Safety Warning

Montelukast carries an FDA Boxed Warning concerning serious neuropsychiatric events.

Patients and caregivers should watch for new or worsening:

• Agitation
• Aggressive behaviour
• Irritability
• Anxiety
• Depression
• Abnormal or vivid dreams
• Sleep disturbances
• Confusion
• Hallucinations
• Restlessness
• Memory problems
• Suicidal thoughts or behaviour

FDA advises that patients taking montelukast should stop the medicine and contact a healthcare professional immediately if new neuropsychiatric symptoms or suicidal thoughts/behaviour occur. Events have been reported in patients with and without a previous history of psychiatric illness.

For allergic rhinitis, FDA recommends reserving montelukast for patients who have an inadequate response to or cannot tolerate alternative therapies.

This warning is particularly important when preparing patient-facing website content for BILAWITH-M.

---

11. Precautions & Warnings

Before taking BILAWITH-M, inform your doctor if you have:

• Kidney disease
• Liver disease
• Previous drug allergies
• A history of psychiatric or behavioural symptoms
• Asthma or other respiratory disease
• Pregnancy or plans to become pregnant
• Breastfeeding
• Other significant medical conditions

Kidney impairment

Bilastine is eliminated largely in unchanged form, and product information should be consulted for patients with renal impairment, particularly when other medicines affecting P-glycoprotein are being used.

Psychiatric history

Tell the physician about any previous psychiatric illness before starting montelukast. FDA specifically recommends discussing psychiatric history and monitoring for neuropsychiatric symptoms.

---

12. Drug Interactions

Inform your doctor about all prescription medicines, OTC medicines, supplements and herbal products.

Particular attention may be required with:

• Medicines affecting gastrointestinal absorption
• Certain P-glycoprotein inhibitors
• Other antihistamines
• Sedating medicines
• Other asthma/allergy medicines

For bilastine, food and fruit juice are particularly relevant because they can reduce drug exposure.

---

13. Alcohol & Driving

Bilastine is generally considered a non-sedating antihistamine, but individual patients may experience dizziness or other impairment.

Patients should determine their individual response before:

• Driving
• Operating machinery
• Working at heights
• Performing other activities requiring full alertness

Alcohol or other sedating substances may increase impairment in susceptible individuals.

---

14. Pregnancy & Breastfeeding

If pregnant, planning pregnancy or breastfeeding, consult a healthcare professional before using BILAWITH-M.

The combination should be used only when the treating physician considers the expected benefit appropriate for the individual patient.

---

15. Use in Children

The artwork contains:

Bilastine 20 mg + Montelukast 10 mg.

This is an adult-strength combination and should not automatically be assumed appropriate for children.

Bilastine 20 mg product information reviewed here is indicated for adults and adolescents aged 12 years and above.

Paediatric use of the fixed-dose combination should be determined according to the current approved product information, age, diagnosis and appropriate individual drug strengths.

---

16. When to Seek Medical Attention

Seek immediate medical attention for:

• Difficulty breathing
• Swelling of the lips, face, tongue or throat
• Severe allergic reaction
• Fainting
• Severe dizziness
• Significant behavioural changes
• Hallucinations
• Severe depression
• Suicidal thoughts or behaviour

Any new neuropsychiatric symptoms while taking montelukast should be promptly discussed with a healthcare professional.

---

17. Storage

Store BILAWITH-M:

• At the temperature specified on the product label.
• In a cool, dry place.
• Protected from excessive heat and moisture.
• Away from direct sunlight.
• Out of reach of children.

Keep the tablets in their original packaging until use.

---

18. Key Features of BILAWITH-M

BILAWITH-M Tablets provide:

• Bilastine 20 mg
• Montelukast equivalent to 10 mg
• Dual antihistamine + leukotriene pathway activity
• Film-coated tablet dosage form
• Prescription formulation
• Ponceau 4R colour as shown on the artwork
• 10 × 10 tablet pack
• Convenient oral dosage form

---

19. Why BILAWITH-M?

BILAWITH-M combines:

Bilastine 20 mg

A selective peripheral H1-antihistamine designed to control histamine-mediated allergic symptoms.

Montelukast 10 mg

A leukotriene receptor antagonist that blocks leukotriene-mediated effects involved in allergic and airway inflammation.

The two ingredients therefore provide different pharmacological mechanisms within one formulation.

However, the presence of montelukast means its important neuropsychiatric safety warning should be considered when determining whether the combination is appropriate.